NCT05885035 is a Phase 1 clinical trial of Calcium Hydroxyapatite in Cellulite, sponsored by Kalpna Kay Durairaj, MD, FACS.

Who is sponsoring NCT05885035?

NCT05885035 is sponsored by Kalpna Kay Durairaj, MD, FACS.

What drugs are being tested in NCT05885035?

Interventions in NCT05885035: Calcium Hydroxyapatite.

Is NCT05885035 still recruiting?

NCT05885035 is currently completed. Last updated 17 July 2023.

Last reviewed 2023-07-17 · How we verify

NCT05885035

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Calcium Hydroxylapatite on Cellulite Dimples in the Buttocks

Completed Phase 1 Last updated 17 July 2023

What this trial tests

Phase 1 trial testing Calcium Hydroxyapatite in Cellulite in 25 participants. Completed in 26 June 2023.

Timeline

1 January 2023

Primary endpoint
26 June 2023

26 June 2023

Quick facts

Lead sponsor	Kalpna Kay Durairaj, MD, FACS
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	1 January 2023
Primary completion	26 June 2023
Estimated completion	26 June 2023
Sites	1 location across United States

Drugs / interventions tested

Calcium Hydroxyapatite — full drug profile →

Conditions studied

Cellulite — all drugs for Cellulite →

Sponsor

Kalpna Kay Durairaj, MD, FACS — full company profile →

Who can join

Adults 21 to 50, female only, with Cellulite. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to test the efficacy of Calcium Hydroxylapatite (CaHA) in treating cellulite dimples in the buttocks. Participants will: * have 3 treatment sessions at weeks 0, 4, and 8 and a final live assessment visit at week 14 * receive approximately 2 syringes per side of the buttocks, per treatment session * have their pictures taken before and after each treatment session, and once more during the final visit

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Safety and Efficacy of Diluted Calcium Hydroxylapatite for the Treatment of Cellulite Dimpling on the Buttocks: Results from an Open-Label, Investigator-Initiated, Single-Center, Prospective Clinical Study.
Durairaj K, Baker O, Yambao M, Linnemann-Heath J, et al · · 2024 · cited 3× · PMID 38253886 · DOI 10.1007/s00266-023-03815-z

Verify or expand the search:

Other trials of Calcium Hydroxyapatite

Trials testing the same drug.

NCT06993558 — Analysis of Safety and Tissue Interaction of Injectable and Energy-based Biosmulators · NA · recruiting

Other recruiting trials for Cellulite

Currently open trials in the same condition.

NCT06791564 — Minimally Invasive Active Release of Septa Bands for Cellulite and Connective Tissue Release for Fibrosis Treatment in B · NA · recruiting

Other Kalpna Kay Durairaj, MD, FACS trials

Trials by the same sponsor.

NCT06604832 — Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05885035 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kalpna Kay Durairaj, MD, FACS
Last refreshed: 17 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05885035.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing